Delivery of Biologics in Cardiovascular Regenerative Medicine

Abstract

Stem cell–based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery. Clinical Pharmacology & Therapeutics (2009); 85, 5, 548–552 doi:10.1038/clpt.2008.295